BioCentury
BioCentury
ARTICLE | Product Development

AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group

By Lauren Martz, Senior Editor
April 12, 2021 10:21 PM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

Agenus Inc.

BCIQ Target Profiles

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)

BCIQ Company Profiles

Agenus Inc.

BCIQ Target Profiles

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedIn
Twitter
RSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedIn
Twitter
RSS